(844) 274-8497



Clinical Trials


The University of Arizona Cancer Center at Dignity Health St. Joseph’s Hospital and Medical Center leads several clinic trials within our Phoenix cancer center.

Below is a list of our active trials. Select the study name for specific information about that trial. For more information about how to participate in any of the clinical trials listed below, contact the Clinical Trials Office at 855.622.6845.

 

ABDOMINAL CANCER

David Row, MD, FACS, FASCRS

PHXE-17-0120-80-15

S1316, Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction

Mital Patel, MD

PHXE-18-500-174-80-15

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

 

BASAL CELL CARCINOMA

Wong, Debra, MD

PHXE-17-0101-80-15

A Phase 2 Study of REGN2810, A Fully Human Monoclonal Antibody to Programmed Death-1, in Patients with Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

 

BLADDER CANCER

Jue Wang, MD

PHXE-18-500-242-80-15

A Randomized, Open Label, Multicenter Phase 2/3 Study to Evaluate the Efficacy and Safety of Rogaratinib (BAY1163877) Compared to Chemotherapy in Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma Who Have Received Prior Platinum-containing Chemotherapy

 

BREAST CANCER

Albert Wendt, MD

PHXA-15-0013-10-15

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer

Albert Wendt, MD

PHXE-16-0167-10-15

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Albert Wendt, MD

PHXE-17-0356-80-15

MonarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, BreastCancer

Albert Wendt, MD

PHXA-17-0242-71-15

Aerobic Interval Exercise Preconditioning to Prevent Cardiometabolic and Neuropsychological Complications of Anthracycline Based Breast Cancer Chemotherapy

Albert Wendt, MD

PHXE-17-0374-10-15

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer

Lora Hebert, MD

PHXE-17-0351-10-15

A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery.

Lora Hebert, MD

PHXE-17-0373-10-15

A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

 

KIDNEY CANCER

Jue Wang, MD

PHXE-17-0114-10-15

A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

 

PRECISION MEDICINE

Jue Wang, MD

PHXE-17-0216-10-15

EAY131: Molecular Analysis for Therapy Choice (MATCH)

 

PROSTATE CANCER

Jue Wang, MD

PHXE-17-0128-80-15

An Open-Label Phase 1/2A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TRC253, and Androgen Receptor Antagonist, in Patients with Metastatic Castration-Resistant Prostate Cancer

 

OVARIAN CANCER

John Farley, MD

PHXE-16-0213-80-15

A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

 

RARE TUMORS

Jue Wang, MD

PHXE-17-0349-10-15

 

SHERLOC: A Phase 2 Study of MM-121 in Combination with Docetaxel versus Docetaxel Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

 

Learn More

For more information or to participate, call the Clinical Trials Office at 855.622.6845.